Skip to content
Colorectal Cancer Clinical Trials

Maryland

Colorectal cancer clinical trials in Maryland

70 colorectal cancer studies are recruiting participants at sites in 23 cities across Maryland as of November 16, 2026, according to ClinicalTrials.gov.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Maryland city with a recruiting study

Baltimore (39), Bethesda (22), Glen Burnie (7), Westminster (5), Elkton (4), Frederick (4), Towson (4), Olney (3), Randallstown (3), Clinton (2), Gaithersburg (2), Largo (2), Lutherville (2), Silver Spring (2), Aberdeen (1), Bel Air (1), Brandywine (1), Columbia (1), Cumberland (1), Easton (1), Kensington (1), Ocean Pines (1), Salisbury (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Recently updated studies in Maryland

Basic details from each study's public record (the 12 most recently updated of 70). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Evaluation for NCI Surgery Branch Clinical Research Protocols

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bethesda
    Registry record
    NCT00001823 · updated
  2. Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

    • Phase 2
    • Ages 18 to 72
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bethesda
    Registry record
    NCT01174121 · updated
  3. Genomic Services Research Program

    • Observational
    • From 1 month, up to 105 years
    • All sexes
    Sponsor
    National Human Genome Research Institute (NHGRI)
    Recruiting in
    Bethesda
    Registry record
    NCT02595957 · updated
  4. Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

    • Phase 1
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bethesda
    Registry record
    NCT04847063 · updated
  5. Shield Post-Approval Study Protocol

    • Observational
    • Ages 45 to 81
    • All sexes
    Sponsor
    Guardant Health, Inc.
    Recruiting in
    Olney
    Registry record
    NCT06880055 · updated
  6. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Baltimore
    Registry record
    NCT06997497 · updated
  7. Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Solstice Oncology, Inc.
    Recruiting in
    Baltimore
    Registry record
    NCT07808151 · updated
  8. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Recruiting in
    Baltimore
    Registry record
    NCT07020221 · updated
  9. Collection of Blood From Patients With Cancer

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bethesda
    Registry record
    NCT00034216 · updated
  10. Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bethesda
    Registry record
    NCT00451022 · updated
  11. Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

    • Phase 1
    • Ages 12 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bethesda
    Registry record
    NCT04222413 · updated
  12. Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

    • Phase 1/2
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bethesda
    Registry record
    NCT06149481 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Maryland on ClinicalTrials.gov.

Ask about studies in Maryland

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call